CytomX Therapeutics (CTMX) Deferred Taxes (2015 - 2017)

CytomX Therapeutics' (CTMX) quarterly Deferred Taxes came in at -$520000.0 in Q4 2017, down 2636.84% on a QoQ basis from -$19000.0 in Q3 2017.

CytomX Therapeutics (CTMX) Deferred Taxes (2015 - 2017) Analysis & Trends

CytomX Therapeutics (CTMX) has 3 years of Deferred Taxes data on file, last reported at -$520000.0 in Q4 2017.

Quarterly Deferred Taxes changed N/A year-over-year to -$520000.0 in Q4 2017, while the trailing twelve-month figure through Dec 2017 was -$513000.0 (down 8650.0% YoY) and the FY2017 annual result came in at -$513000.0, down 8650.0% from the prior year.
Deferred Taxes slipped to -$520000.0 in Q4 2017, from -$19000.0 in the prior quarter.
In the past five years, Deferred Taxes ranged from a high of $25000.0 in Q2 2017 to a low of -$520000.0 in Q4 2017.
A 3-year average of -$72000.0 and a median of $3000.0 in 2015 frame the typical range for Deferred Taxes.
The widest YoY moves for Deferred Taxes: up 733.33% in 2017, down 66.67% in 2017.
Tracing CTMX's Deferred Taxes over 3 years: stood at $3000.0 in 2015, then changed by 0.0% to $3000.0 in 2016, then slumped by 17433.33% to -$520000.0 in 2017.
The last three Deferred Taxes figures came in at -$520000.0 (Q4 2017), -$19000.0 (Q3 2017), and $25000.0 (Q2 2017), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Deferred Taxes (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-69.70 Mn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	194.40 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-137,876.64
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	2.66 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	CytomX Therapeutics	732.14 Mn	401.86 Mn	-	-

Download Data